These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 30111881)
1. Contribution of RAD51D germline mutations in breast and ovarian cancer in Greece. Konstanta I; Fostira F; Apostolou P; Stratikos E; Kalfakakou D; Pampanos A; Kollia P; Papadimitriou C; Konstantopoulou I; Yannoukakos D J Hum Genet; 2018 Nov; 63(11):1149-1158. PubMed ID: 30111881 [TBL] [Abstract][Full Text] [Related]
2. About 1% of the breast and ovarian Spanish families testing negative for BRCA1 and BRCA2 are carriers of RAD51D pathogenic variants. Gutiérrez-Enríquez S; Bonache S; de Garibay GR; Osorio A; Santamariña M; Ramón y Cajal T; Esteban-Cardeñosa E; Tenés A; Yanowsky K; Barroso A; Montalban G; Blanco A; Cornet M; Gadea N; Infante M; Caldés T; Díaz-Rubio E; Balmaña J; Lasa A; Vega A; Benítez J; de la Hoya M; Diez O Int J Cancer; 2014 May; 134(9):2088-97. PubMed ID: 24130102 [TBL] [Abstract][Full Text] [Related]
3. Mutation Analysis of the RAD51C and RAD51D Genes in High-Risk Ovarian Cancer Patients and Families from the Czech Republic. Janatova M; Soukupova J; Stribrna J; Kleiblova P; Vocka M; Boudova P; Kleibl Z; Pohlreich P PLoS One; 2015; 10(6):e0127711. PubMed ID: 26057125 [TBL] [Abstract][Full Text] [Related]
4. Recurrent moderate-risk mutations in Finnish breast and ovarian cancer patients. Nurmi A; Muranen TA; Pelttari LM; Kiiski JI; Heikkinen T; Lehto S; Kallioniemi A; Schleutker J; Bützow R; Blomqvist C; Aittomäki K; Nevanlinna H Int J Cancer; 2019 Nov; 145(10):2692-2700. PubMed ID: 30927251 [TBL] [Abstract][Full Text] [Related]
5. Associations between RAD51D germline mutations and breast cancer risk and survival in BRCA1/2-negative breast cancers. Chen X; Li Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y Ann Oncol; 2018 Oct; 29(10):2046-2051. PubMed ID: 30165555 [TBL] [Abstract][Full Text] [Related]
6. BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer. Weber-Lassalle N; Hauke J; Ramser J; Richters L; Groß E; Blümcke B; Gehrig A; Kahlert AK; Müller CR; Hackmann K; Honisch E; Weber-Lassalle K; Niederacher D; Borde J; Thiele H; Ernst C; Altmüller J; Neidhardt G; Nürnberg P; Klaschik K; Schroeder C; Platzer K; Volk AE; Wang-Gohrke S; Just W; Auber B; Kubisch C; Schmidt G; Horvath J; Wappenschmidt B; Engel C; Arnold N; Dworniczak B; Rhiem K; Meindl A; Schmutzler RK; Hahnen E Breast Cancer Res; 2018 Jan; 20(1):7. PubMed ID: 29368626 [TBL] [Abstract][Full Text] [Related]
7. Analysis of RAD51D in ovarian cancer patients and families with a history of ovarian or breast cancer. Thompson ER; Rowley SM; Sawyer S; kConfab ; Eccles DM; Trainer AH; Mitchell G; James PA; Campbell IG PLoS One; 2013; 8(1):e54772. PubMed ID: 23372765 [TBL] [Abstract][Full Text] [Related]
8. A Finnish founder mutation in RAD51D: analysis in breast, ovarian, prostate, and colorectal cancer. Pelttari LM; Kiiski J; Nurminen R; Kallioniemi A; Schleutker J; Gylfe A; Aaltonen LA; Leminen A; Heikkilä P; Blomqvist C; Bützow R; Aittomäki K; Nevanlinna H J Med Genet; 2012 Jul; 49(7):429-32. PubMed ID: 22652533 [TBL] [Abstract][Full Text] [Related]
9. Germline RAD51C mutations in ovarian cancer susceptibility. Coulet F; Fajac A; Colas C; Eyries M; Dion-Minière A; Rouzier R; Uzan S; Lefranc JP; Carbonnel M; Cornelis F; Cortez A; Soubrier F Clin Genet; 2013 Apr; 83(4):332-6. PubMed ID: 22725699 [TBL] [Abstract][Full Text] [Related]
10. Germline loss-of-function variants in the BARD1 gene are associated with early-onset familial breast cancer but not ovarian cancer. Weber-Lassalle N; Borde J; Weber-Lassalle K; Horváth J; Niederacher D; Arnold N; Kaulfuß S; Ernst C; Paul VG; Honisch E; Klaschik K; Volk AE; Kubisch C; Rapp S; Lichey N; Altmüller J; Lepkes L; Pohl-Rescigno E; Thiele H; Nürnberg P; Larsen M; Richters L; Rhiem K; Wappenschmidt B; Engel C; Meindl A; Schmutzler RK; Hahnen E; Hauke J Breast Cancer Res; 2019 Apr; 21(1):55. PubMed ID: 31036035 [TBL] [Abstract][Full Text] [Related]
11. Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D. Yang X; Song H; Leslie G; Engel C; Hahnen E; Auber B; Horváth J; Kast K; Niederacher D; Turnbull C; Houlston R; Hanson H; Loveday C; Dolinsky JS; LaDuca H; Ramus SJ; Menon U; Rosenthal AN; Jacobs I; Gayther SA; Dicks E; Nevanlinna H; Aittomäki K; Pelttari LM; Ehrencrona H; Borg Å; Kvist A; Rivera B; Hansen TVO; Djursby M; Lee A; Dennis J; Bowtell DD; Traficante N; Diez O; Balmaña J; Gruber SB; Chenevix-Trench G; Investigators K; Jensen A; Kjær SK; Høgdall E; Castéra L; Garber J; Janavicius R; Osorio A; Golmard L; Vega A; Couch FJ; Robson M; Gronwald J; Domchek SM; Culver JO; de la Hoya M; Easton DF; Foulkes WD; Tischkowitz M; Meindl A; Schmutzler RK; Pharoah PDP; Antoniou AC J Natl Cancer Inst; 2020 Dec; 112(12):1242-1250. PubMed ID: 32107557 [TBL] [Abstract][Full Text] [Related]
12. Clinical characteristics and survival analysis of Chinese ovarian cancer patients with RAD51D germline mutations. Yao H; Li N; Yuan H BMC Cancer; 2022 Dec; 22(1):1337. PubMed ID: 36544182 [TBL] [Abstract][Full Text] [Related]
13. Loss of function germline mutations in RAD51D in women with ovarian carcinoma. Wickramanayake A; Bernier G; Pennil C; Casadei S; Agnew KJ; Stray SM; Mandell J; Garcia RL; Walsh T; King MC; Swisher EM Gynecol Oncol; 2012 Dec; 127(3):552-5. PubMed ID: 22986143 [TBL] [Abstract][Full Text] [Related]
14. Large-scale meta-analysis of mutations identified in panels of breast/ovarian cancer-related genes - Providing evidence of cancer predisposition genes. Suszynska M; Klonowska K; Jasinska AJ; Kozlowski P Gynecol Oncol; 2019 May; 153(2):452-462. PubMed ID: 30733081 [TBL] [Abstract][Full Text] [Related]
15. Association Between Loss-of-Function Mutations Within the FANCM Gene and Early-Onset Familial Breast Cancer. Neidhardt G; Hauke J; Ramser J; Groß E; Gehrig A; Müller CR; Kahlert AK; Hackmann K; Honisch E; Niederacher D; Heilmann-Heimbach S; Franke A; Lieb W; Thiele H; Altmüller J; Nürnberg P; Klaschik K; Ernst C; Ditsch N; Jessen F; Ramirez A; Wappenschmidt B; Engel C; Rhiem K; Meindl A; Schmutzler RK; Hahnen E JAMA Oncol; 2017 Sep; 3(9):1245-1248. PubMed ID: 28033443 [TBL] [Abstract][Full Text] [Related]
16. RAD51C germline mutations found in Spanish site-specific breast cancer and breast-ovarian cancer families. Blanco A; Gutiérrez-Enríquez S; Santamariña M; Montalban G; Bonache S; Balmaña J; Carracedo A; Diez O; Vega A Breast Cancer Res Treat; 2014 Aug; 147(1):133-43. PubMed ID: 25086635 [TBL] [Abstract][Full Text] [Related]
17. Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer. Kast K; Rhiem K; Wappenschmidt B; Hahnen E; Hauke J; Bluemcke B; Zarghooni V; Herold N; Ditsch N; Kiechle M; Braun M; Fischer C; Dikow N; Schott S; Rahner N; Niederacher D; Fehm T; Gehrig A; Mueller-Reible C; Arnold N; Maass N; Borck G; de Gregorio N; Scholz C; Auber B; Varon-Manteeva R; Speiser D; Horvath J; Lichey N; Wimberger P; Stark S; Faust U; Weber BH; Emons G; Zachariae S; Meindl A; Schmutzler RK; Engel C; J Med Genet; 2016 Jul; 53(7):465-71. PubMed ID: 26928436 [TBL] [Abstract][Full Text] [Related]
18. UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes: Hanson H; Kulkarni A; Loong L; Kavanaugh G; Torr B; Allen S; Ahmed M; Antoniou AC; Cleaver R; Dabir T; Evans DG; Golightly E; Jewell R; Kohut K; Manchanda R; Murray A; Murray J; Ong KR; Rosenthal AN; Woodward ER; Eccles DM; Turnbull C; Tischkowitz M; ; Lalloo F J Med Genet; 2023 May; 60(5):417-429. PubMed ID: 36411032 [TBL] [Abstract][Full Text] [Related]
19. Inherited Mutations in Women With Ovarian Carcinoma. Norquist BM; Harrell MI; Brady MF; Walsh T; Lee MK; Gulsuner S; Bernards SS; Casadei S; Yi Q; Burger RA; Chan JK; Davidson SA; Mannel RS; DiSilvestro PA; Lankes HA; Ramirez NC; King MC; Swisher EM; Birrer MJ JAMA Oncol; 2016 Apr; 2(4):482-90. PubMed ID: 26720728 [TBL] [Abstract][Full Text] [Related]
20. BRCA1 and BRCA2 germline mutations in Uruguayan breast and breast-ovarian cancer families. Identification of novel mutations and unclassified variants. Delgado L; Fernández G; Grotiuz G; Cataldi S; González A; Lluveras N; Heguaburu M; Fresco R; Lens D; Sabini G; Muse IM Breast Cancer Res Treat; 2011 Jul; 128(1):211-8. PubMed ID: 21190077 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]